Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945772 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
A Phase 2 study of Retinitis Pigmentosa and Eye Diseases, sponsored by Nanoscope Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT04945772: Completed Phase 2 study of Retinitis Pigmentosa and Eye Diseases, sponsored by Nanoscope Therapeutics.
NCT04945772 is a Phase 2 study of Retinitis Pigmentosa and Eye Diseases that has completed, run by Nanoscope Therapeutics. The registered enrollment target is 27 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (90% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04945772, a Phase 2 study of Retinitis Pigmentosa and Eye Diseases, has completed, sponsored by Nanoscope Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
Primary Outcome
Change from Baseline in the Freiburg Visual Acuity (quantitative LogMAR) score for the study eye at Week 52.
Conditions Studied
Interventions
- BIOLOGICAL Gene Therapy Product-MCO-010
- PROCEDURE Sham Injection
Study Locations (6)
Texas
- Nanoscope Clinical Site - Houston
- Nanoscope Clinical Site - McAllen
California
- Nanoscope Clinical Site - Beverly Hills
Florida
- Nanoscope Clinical Site - Pensacola
North Dakota
- Nanoscope Clinical Site - Fargo
Other
- Nanoscope Clinical Site - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 2 |
What the finished NCT04945772 record still lists
NCT04945772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (90% lower).
The record links to 7 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 2 interventions - of which Gene Therapy Product-MCO-010 is the first listed.
NCT04945772 lists 6 locations in 5 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT04945772 about?
NCT04945772 is a clinical study titled "Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]". The purpose of the study is to evaluate the safety and efficacy of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (MCO-010).
What is the current status of trial NCT04945772?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2021-07-13. Estimated completion is 2024-01-18.
What conditions does trial NCT04945772 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Eye Diseases, Retinal Degeneration, Eye Diseases, Hereditary, Retinal Dystrophies.
What interventions are being tested in trial NCT04945772?
The interventions under investigation include: Gene Therapy Product-MCO-010 (BIOLOGICAL), Sham Injection (PROCEDURE).
Who is sponsoring clinical trial NCT04945772?
This trial is sponsored by Nanoscope Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04945772 being conducted?
This trial has 6 study locations across California, Florida, North Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04945772's enrollment target sits among peer trials
27 23rd of 37 higher than 15 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
RECRUITING · Phase 2
-
Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
COMPLETED · Phase 2
-
Trial of Oral Valproic Acid for Retinitis Pigmentosa
COMPLETED · Phase 2
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI